Ac-FLTD-CMK is a gasdermin D (GSDMD)-derived inhibitor, is a specific inflammatory caspases inhibitor. Ac-FLTD-CMK is effective against caspases-1 (IC50 of 46.7 nM), caspases-4 (IC50 of 1.49 μM), caspases-5 (IC50 of 329 nM), and caspases-11 , but not the apoptotic caspases such as caspase-3.
Ac-IETD-AFC is a fluorogenic substrate of caspase-8, caspase-3, caspase-10, and granzyme B.
Ac-IETD-AFC is a fluorogenic substrate of caspase-8, caspase-3, caspase-10, and granzyme B.
Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM.
Ac-YVAD-cmk is a selective ireversible inhibitor of caspase-1 (interleukin-1β converting enzyme, ICE) with some activity also against caspase-4.
Ac-YVAD-cmk is a selective ireversible inhibitor of caspase-1 (interleukin-1β converting enzyme, ICE) with some activity also against caspase-4.
Ac2-26 TFA, an active N-terminal peptide of adiponectin A1 (AnxA1), alleviates acute lung injury induced by ischemia-reperfusion. Ac2-26 also decreased AnxA1 protein expression and inhibited the activation of NF-κB and MAPK pathways in damaged lung tissue. Sequence Shortening:...
Ac2-26 TFA, an active N-terminal peptide of adiponectin A1 (AnxA1), alleviates acute lung injury induced by ischemia-reperfusion. Ac2-26 also decreased AnxA1 protein expression and inhibited the activation of NF-κB and MAPK pathways in damaged lung tissue. Sequence Shortening:...